← Back to Patent Explorer
US4919915A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for detecting the ability to prevent red-to-green congophilic birefringence

Assignee: DMS Pharmaceutical Inc
•
Filing: 1989-02-27
•
Granted: 1990-04-24
•
Expires: 2009-02-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for detecting the ability of a compound to prevent development of red-to-green congophilic birefringence. The method is carried out by contacting the compound with dense microspheres which are derived from mammalian brain tissue and which, when disrupted, display red-to-green congophilic birefringence upon staining with Congo Red dye under conditions such that said dense microspheres are disrupted. Thereafter the disrupted dense microspheres are stained with Congo Red dye and any development of red-to-green congophilic birefringence in the stained disrupted dense microspheres is detected.

Inventors

  • 👤 Paul Averback

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 15:01
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5082; G01N33/5088; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/40; A61K31/41; A61K31/42; A61K31/495; A61K31/505; A61K31/55; A61K31/63; A61K31/655; A61K31/70; A61P; A61P25/00; A61P25/28; A61P43/00; C; C07; C07H; C07H17/00; C07H17/04; C07H17/08; C07H19/00; C07H19/02; C07H19/04; C07H19/06; G01N33/68; G01N33/6893; G01N33/6896; G01N2333/00; G01N2333/435; G01N2333/46; G01N2333/47; G01N2333/4701; G01N2333/4709; G01N2500/00; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10T; Y10T436/00; Y10T436/25; Y10T436/25375

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 130 words
A method for detecting the ability of a compound to prevent red-to-green congophilic birefringence as a possible indication of the compound's ability to impede amyloid formation comprising the steps of (i) contacting a compound with a reagent in a first sample, wherein the reagent consists essentially of dense microspheres which are derived from mammalian brain tissue and which, when disrupted, display red-to-green congophilic birefringence upon standing with Congo Red dye, under conditions such that said dense microspheres are disrupted in said first sample; thereafter (ii) staining a test material selected from the group consisting of the first sample or a portion thereof which contains at least some of the disrupted dense microspheres with Congo Red dye; and (iii) detecting any development of red-to-green congophilic birefringence in the stained test material.
Claim 2
Independent Claim 130 words
A method for detecting the ability of a compound to prevent red-to-green congophilic birefringence as a possible indication of the compound's ability to impede amyloid formation comprising the steps of (i) contacting a compound with a reagent in a first sample, wherein the reagent consists essentially of dense microspheres which are derived from mammalian brain tissue and which, when disrupted, display red-to-green congophilic birefringence upon standing with Congo Red dye, under conditions such that said dense microspheres are disrupted in said first sample; thereafter (ii) staining a test material selected from the group consisting of the first sample or a portion thereof which contains at least some of the disrupted dense microspheres with Congo Red dye; and (iii) detecting any development of red-to-green congophilic birefringence in the stained test material.
Claim 3
Dependent Claim 48 words
The method according to claim 1 which further comprises (iv) comparing any detected development of red-to-green congophilic birefringence of step (iii) with any detected development of red-to-green congophilic birefringence obtained by carrying out said disrupting, staining, and detecting with reagent which has not been contacted with said compound.
Claim 4
Dependent Claim 53 words
The method according to claim 1 which further comprises (iv) comparing any detected development of red-to-green congophilic birefringence of step (iii) with any detected development of red-to-green congophilic birefringence obtained by carrying out said disrupting, staining, and detecting with reagent which has been contacted with a 1% aqueous solution of Congo Red dye.
Claim 5
Dependent Claim 23 words
The method according to claim 1, wherein said first sample comprises tissue into which each of said reagent and said compound is introduced.
Claim 6
Dependent Claim 18 words
The method according to claim 4, wherein each of said reagent and said compound is introduced in vivo.
Claim 7
Dependent Claim 12 words
The method according to claim 5, wherein said tissue is brain tissue.
Claim 8
Dependent Claim 31 words
The method according to claim 4, wherein said compound is introduced in vivo into an animal and said reagent is introduced in vitro into a tissue sample isolated from said animal.
Claim 9
Dependent Claim 12 words
The method according to claim 7, wherein said tissue is brain tissue.
Claim 10
Dependent Claim 26 words
The method according to claim 1, wherein step (i) includes introducing said reagent onto a glass or plastic surface before disruption thereon of said dense microspheres.
Claim 11
Dependent Claim 12 words
The method according to claim 9, wherein said disruption is effected mechanically.
Claim 12
Dependent Claim 20 words
The method according to claim 9, wherein said disruption is effected by subjecting said dense microspheres to an enzymatic treatment.
Claim 13
Dependent Claim 25 words
The method according to claim 9, wherein said disruption is effected by exposing said dense microspheres to pH conditions sufficient to disrupt said dense microspheres.
Claim 14
Dependent Claim 25 words
The method according to claim 9, wherein said disruption is effected by exposing said dense microspheres to temperature conditions sufficient to disrupt said dense microspheres.

References Cited (Backward Citations)

US4666829A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-04-23 1993-10-23 1994-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-04-23 1997-10-23 1998-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-04-23 2001-10-23 2002-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag